Persistent organ dysfunction plus death: a novel, composite outcome measure for critical care trials
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Introduction: Due to resource limitations, few critical care interventions have been rigorously evaluated with adequately powered randomized clinical trials (RCTs). There is a need to improve the efficiency of RCTs in critical care so that more definitive high quality RCTs can be completed with the available resources. The objective of this study was to validate and demonstrate the utility of a novel composite outcome measure, persistent organ dysfunction (POD) plus death, for clinical trials of critically ill patients. Methods: We performed a secondary analysis of a dataset from a prospective randomized trial involving 38 intensive care units (ICUs) in Canada, Europe, and the United States. We define POD as the persistence of organ dysfunction requiring supportive technologies during the convalescent phase of critical illness and it is present when a patient has an ongoing requirement for vasopressors, dialysis, or mechanical ventilation at the outcome assessments time points. In 600 patients enrolled in a randomized trial of nutrition therapy and followed prospectively for six months, we evaluated the prevalence of POD and its association with outcome. Results: At 28 days, 2.3% of patients had circulatory failure, 13.7% had renal failure, 8.7% had respiratory failure, and 27.2% had died, for an overall prevalence of POD + death = 46.0%. Of survivors at Day 28, those with POD, compared to those without POD, had a higher mortality rate in the six-month follow-up period, had longer ICU and hospital stays, and a reduced quality of life at three months. Given these rates of POD + death and using a two-sided Chi-squared test at alpha = 0.05, we would require 616 patients per arm to detect a 25% relative risk reduction (RRR) in mortality, but only 286 per arm to detect the same RRR in POD + mortality. Conclusions: POD + death may be a valid composite outcome measure and compared to mortality endpoints, may reduce the sample size requirements of clinical trials of critically ill patients. Further validation in larger clinical trials is required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schweickert, W. D., Pohlman, M. C., Pohlman, A. S., Nigos, C., Pawlik, A. J., Esbrook, C. L., Spears, L., Miller, M., Franczyk, M., Deprizio, D., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60658-9 · Cited by 3,339
The development of a comorbidity index with physical function as the outcome
GROLL, D., TO, T., BOMBARDIER, C., & WRIGHT, J. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.10.018 · Cited by 1,198
Effect of Systemic Glucocorticoids on Exacerbations of Chronic Obstructive Pulmonary Disease
Niewoehner, D. E., Erbland, M. L., Deupree, R. H., Collins, D., Gross, N. J., Light, R. W., Anderson, P., & Morgan, N. A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906243402502 · Cited by 875
Empirical Fluconazole versus Placebo for Intensive Care Unit Patients: A Randomized Trial
Schuster, M. G., Edwards, J. E., Sobel, J. D., Darouiche, R. O., Karchmer, A. W., Hadley, S., Slotman, G., Panzer, H., Biswas, P., & Rex, J. H. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-2-200807150-00004 · Cited by 210
Cited by
High versus low blood-pressure target in patients with septic shock.
Asfar, P., Meziani, F., Hamel, J.-F., Grelon, F., Megarbane, B., Anguel, N., Mira, J.-P., Dequin, P.-F., Gergaud, S., Weiss, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312173 · Cited by 1,239
Lower versus Higher Hemoglobin Threshold for Transfusion in Septic Shock
Holst, L. B., Haase, N., Wetterslev, J., Wernerman, J., Guttormsen, A. B., Karlsson, S., Johansson, P. I., Åneman, A., Vang, M. L., Winding, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406617 · Cited by 899
Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit
Lamontagne, F., Masse, M.-H., Menard, J., Sprague, S., Pinto, R., Heyland, D. K., Cook, D. J., Battista, M.-C., Day, A. G., Guyatt, G. H., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200644 · Cited by 350
Self-citationAsfar, P., Schortgen, F., Boisramé-Helms, J., Charpentier, J., Guérot, E., Megarbane, B., Grimaldi, D., Grelon, F., Anguel, N., Lasocki, S., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30046-2 · Cited by 303
for the Canadian Critical Care Trials Group., Lamontagne, F., Meade, M. O., Hébert, P. C., Asfar, P., Lauzier, F., Seely, A. J. E., Day, A. G., Mehta, S., Muscedere, J., et al. (2016) · Intensive Care Medicine · doi:10.1007/s00134-016-4237-3 · Cited by 230
Self-citationThe LOVIT-COVID Investigators, O. B. O. T. C. C. C. T. G., Florescu, S., Stanciu, D., Zaharia, M., Kosa, A., Codreanu, D., Fareed, K., Kidwai, A., Kaye, C., Coutts, A., et al. (2023) · JAMA · doi:10.1001/jama.2023.21407 · Cited by 55
Self-citation
Metadata
- Authors
- Heyland, D. K., Muscedere, J., Drover, J., Jiang, X., Day, A. G., & the Canadian Critical Care Trials Group
- Venue
- Critical Care
- Published
- 2011-03-18
- Volume
- 15
- Issue
- 2
- Pages
- R98-R98
- ISSN
- 1364-8535 (ISSN-L)
- OpenAlex
- W2116583941
- Cited by
- 56
- References
- 5
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.